Merck & Co., Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)
Merck & Co., Inc. (MRK) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) of -$67.00 million for the 12-month period ending 2010-12-31, per its 10-K filed 2011-02-28.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements · last filed 2011-02-28
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for the quarter ending 2010-12-31 was -$2.50M.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for the quarter ending 2010-09-30 was -$1.90M.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for the quarter ending 2010-06-30 was -$8.40M.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for the quarter ending 2010-03-31 was -$54.20M.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for fiscal 2010 was -$67.00M.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for fiscal 2009 was -$76.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) 12 month |
|---|---|---|---|---|
| 2010-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | -$4.40M derived: sum of 2 quarters · filed 2011-02-28 | -$12.80M derived: sum of 3 quarters · filed 2011-02-28 | -$67.00M 10-K · filed 2011-02-28 |
| 2010-09-30 | -$1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | -$10.30M derived: sum of 2 quarters · filed 2010-11-08 | -$64.50M 10-Q · filed 2010-11-08 | -$71.90M derived: sum of 4 quarters · filed 2011-02-28 |
| 2010-06-30 | -$8.40M 10-Q · filed 2010-08-06 | -$62.60M 10-Q · filed 2010-08-06 | -$70.00M derived: sum of 3 quarters · filed 2011-02-28 | -$79.20M derived: sum of 4 quarters · filed 2011-02-28 |
| 2010-03-31 | -$54.20M derived: 10-K 12 month − 3 quarters · filed 2011-02-28 | -$61.60M derived: sum of 2 quarters · filed 2011-02-28 | -$70.80M derived: sum of 3 quarters · filed 2011-02-28 | -$103.90M derived: sum of 4 quarters · filed 2011-02-28 |
| 2009-12-31 | -$7.40M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | -$16.60M derived: sum of 2 quarters · filed 2011-02-28 | -$49.70M derived: sum of 3 quarters · filed 2011-02-28 | -$76.00M 10-K · filed 2011-02-28 |
| 2009-09-30 | -$9.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | -$42.30M derived: sum of 2 quarters · filed 2010-11-08 | -$68.60M 10-Q · filed 2010-11-08 | |
| 2009-06-30 | -$33.10M 10-Q · filed 2010-08-06 | -$59.40M 10-Q · filed 2010-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |